- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03969238
Utilizing Helpline for Opioid Dependence Treatment
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The proposed specific aims are to:
- Test if the helpline is a resourceful tool for patients with opioid use disorder looking for referrals and support to access treatment. The opioid helpline will provide individuals with opioid use disorder seeking treatment, direct access to a live person who can answer questions regarding referrals and various treatment programs. The helpline will also follow-up on treatment compliance and offer support and motivational techniques for these individuals to stay engaged in treatment
- Test if the helpline is a resourceful tool for patients with new onset of pain or chronic pain being prescribed opioids. The opioid helpline will provide these individuals the necessary educational materials on managing pain safely while avoiding misuse. It will offer free imagery guided meditation and other non-pharmacological tools to help with pain management.
- Test if providers find the opioid helpline helpful and resourceful for their practice and are willing to refer patients to the helpline.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22903
- UVA Center for Leading Edge Addiction Research
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
We plan to pilot this model in a small rural area with low accessibility to specialized treatment. We will specifically target the area of county of Wise as it is an area with one of the highest rate of opioid addiction and overdose related deaths in the state.
UVA hospital: we plan to pilot this model at UVA hospital because it is a health care system offering care to a diverse population from urban and rural areas.
The providers will be educated regarding the goals and objectives of the helpline: Any specialty physicians, nurses including dentists that prescribes opioids within Virginia They will be asked to have flyers about the helpline in their office and refer patients who are prescribed opioids to get more support from the helpline.
La description
Inclusion Criteria:
Participant Criteria:
- Age greater than or equal to 18 years.
- A formal diagnosis of Opioid Use Disorder (OUD) by a health care provider or
- If no formal diagnosis of OUD, having a self-reported concern with opioid use or addiction.
- An individual seeking to reduce opioid use.
- An individual concerned about opioids prescribed for management of new-onset pain or chronic pain.
Provider Criteria:
- University of Virginia: Providers of any specialties within VA including dentists that prescribes opioids.
- County of Wise: Providers of any specialties including dentists that prescribes opioids.
Exclusion Criteria:
Participant Criteria:
- Individuals under 18 years of age.
- Individuals seeking treatment for non-opioid substance use disorders
- Individuals who have no pain issues
- Individuals located outside of Virginia.
Provider Criteria:
Providers outside the designated regions.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Patients/Providers
Of the1,000 participants: (1) 900 will enroll as participants who use the helpline resources via verbal consent and (2) 100 will enroll as providers via online consent prior to survey data collection.
|
This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises.
For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment.
The opioid helpline will provide a central resource for direct services and a portal for community services.
It will also serve as a referral resource for health-care professionals.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Participant Opioid Helpline Survey
Délai: up to a year
|
Primary outcomes measure the rating of the Helpline by the patients.
They will be sent surveys that will ask the patients to rate the services they receive on a scale of 1 to 10, with 1 meaning they are very dissatisfied and 10 meaning they are very satisfied.
|
up to a year
|
|
Provider Opioid Helpline Survey
Délai: up to a year
|
Primary outcomes measure the rating of the Helpline by the providers.
They will be sent surveys that will ask the providers to rate the services they receive on a scale of 1 to 10, with 1 meaning they are very dissatisfied and 10 meaning they are very satisfied.
|
up to a year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants reached versus called.
Délai: up to a year
|
Total number of contacts to the Helpline compared to the number that prescreened and the number consented.
|
up to a year
|
|
Number of participants who continued to access the services of Helpline
Délai: up to a year
|
The investigator will measure the number of participants who continued to access the services of Helpline up to a year.
|
up to a year
|
|
New General Self-Efficacy Measure
Délai: up to a year
|
By using this survey, the investigator will determine the participant's ability to handle the situation that prompted the participant to call the Helpline originally.
|
up to a year
|
|
Opioid Helpline Study Screen Form
Délai: up to a year
|
This will be use to collect demographic information for individuals who self-identify as needing help or resources from the Helpline.
|
up to a year
|
|
Referral follow-ups
Délai: up to a year
|
Assess which referrals were followed up on by the participants.
|
up to a year
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Nassima Ait-Daoud Tiouririne, M.D., University of Virginia
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Troubles liés aux stupéfiants
- Manifestations neurologiques
- Maladies du système nerveux
- Les troubles mentaux
- Manifestations neurocomportementales
- Troubles liés à une substance
- Troubles induits chimiquement
- Troubles de la perception
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Troubles liés aux opioïdes
- Agnosie
Autres numéros d'identification d'étude
- 21376
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .